



# MAPLE-BROWN ABBOTT

INVESTMENT MANAGERS SINCE 1984

## Maple-Brown Abbott Asia Pacific ex-Japan Fund

31 July 2020

**Investment objective**  
The investment objective for the Fund is to outperform the benchmark over rolling four year periods. The Fund is a sub-fund of Maple-Brown Abbott Funds p.l.c. which is an open-ended investment company with variable capital and segregated liability between sub-funds. The company is incorporated with limited liability under the laws of Ireland and is established pursuant to the UCITS Regulations. The Fund is available in Euro, US Dollar, Sterling and SGD share classes.

**Performance**

**Institutional Euro Class (USD)** NAV: EUR 1.1893

ISIN: IE00B284YZ06	1 Month %	3 Months %	YTD %	1 Year %	3 Years % p.a.	4 Years % p.a.	5 Years % p.a.	Since Inception 19.10.07 % p.a.
Fund*	7.4	11.7	-14.6	-10.4	-2.8	4.4	3.0	2.7
Benchmark <sup>1</sup>	7.9	16.4	1.3	9.0	4.1	8.9	7.0	2.8


\* The Fund's performance is based on the movement in net asset value per share and is before tax and after all fees and charges. Tax credits are not included in the performance figures.  
Inception date: 19 October 2007  
<sup>1</sup> Benchmark: MSCI AC Asia Pacific ex-Japan Net Index

**Market commentary**  
The Asia Pacific ex-Japan region posted strong gains over the month of July, led by a number of large technology companies in North Asian markets. Gold also surged during the month to record highs (in nominal terms) as investors continued to pile into the precious metal amid a weaker US currency, record low yields and an uncertain macroeconomic and geopolitical environment. China's fiscal and monetary stimulus is finding traction as economic data released during the month showed a strong rebound. Key highlights were China's positive second quarter GDP growth (versus a decline in the prior quarter), a rebound in the Purchasing Manager's Index and improving export data. Meanwhile economic conditions in ASEAN remain challenging, and central banks in Malaysia and Indonesia cut interest rates by 25 basis points during the month. The region outperformed the global benchmark over the period.

Regionally, the best performing markets during the month were Taiwan (+16.3%), Pakistan (+13.5%) and India (+10.4%) in USD terms, while the worst performing markets were Thailand (-2.9%), the Philippines (-2.9%) and Hong Kong (-0.7%). On a sector basis, the best performing sectors were Information Technology (+17.9%), Consumer Discretionary (+12.7%) and Materials (+9.8%), while the worst performing sectors were Utilities (+0.8%), Real Estate (+1.0%) and Industrials (+2.1%).

**Fund commentary**  
The Fund returned 7.4% in USD terms for the month, underperforming the benchmark by 0.5%. Positive contributors came from Information Technology, Financials and Utilities sectors. Detractors came from Consumer Discretionary, Materials and Energy sectors.

Key contributors during the month included our positions in Taiwan Semiconductor Manufacturing Company (overweight), Infosys (overweight) and China Life Insurance (overweight). Detractors from performance were Alibaba (not held), Health and Happiness (H&H) International Holdings (overweight) and Siam Commercial Bank (overweight).



Value and balance sheet characteristics	Fund	Market Overall*
	Price:Earnings Ratio	9.4
Price:Cash Flow Ratio	5.6	9.9
Price:Net Tangible Assets Ratio	0.9	1.8
Dividend Yield %	3.9	2.6
Balance Sheet Strength**	0.46	0.44

\* Represents our quantitative data which includes 93.0% of the index weight of the stocks in the Benchmark, plus non-Benchmark stocks.  
\*\* Cash Flow/Total Liabilities  
The figures shown above are based on 2021 estimates.

Risk measures	Fund	Benchmark
	Monthly Volatility (% p.a.)*	20.8
Tracking Error (ex-ante)	5.3	
Beta vs Benchmark	1.0	
Information Ratio (% p.a.)*	0.0	

\* Since inception

Significant holdings	Fund %	Benchmark %
	Taiwan Semiconductor Manufact. Co	7.2
Samsung Electronics	6.9	4.1
BHP Billiton	3.1	1.2
Reliance Industries	2.6	1.2
NetEase	2.5	0.6

Performance of share classes	Institutional Euro (EUR)								NAV: EUR 1.1893
	ISIN:	1 Month	3 Months	YTD	1 Year	3 Years	4 Years	5 Years	Since Inception
	IE00B284YZ06	%	%	%	%	% p.a.	% p.a.	% p.a.	19.10.07
									% p.a.
	Fund	2.0	3.5	-18.9	-15.6	-2.9	2.9	1.6	4.2
	Benchmark <sup>1</sup>	2.5	7.8	-3.8	2.6	4.0	7.4	5.6	4.3
Institutional Sterling (GBP)								NAV: GBP 0.7743	
	ISIN:	1 Month	3 Months	YTD	1 Year	3 Years	4 Years	5 Years	Since Inception
	IE00B284Z023	%	%	%	%	% p.a.	% p.a.	% p.a.	16.04.14
									% p.a.
	Fund	1.1	7.4	-13.7	-16.4	-2.6	4.7	6.7	6.0
	Benchmark <sup>1</sup>	1.6	11.8	2.3	1.7	4.3	9.2	10.8	9.4
Institutional Singapore Dollar (SGD)								NAV: SGD 1.5417	
	ISIN:	1 Month	3 Months	YTD	1 Year	3 Years	4 Years	5 Years	Since Inception
	IE00BQWJN968	%	%	%	%	% p.a.	% p.a.	% p.a.	16.10.14
									% p.a.
	Fund	5.5	8.8	-12.9	-10.2	-2.4	4.9	3.1	3.4
	Benchmark <sup>1</sup>	6.1	13.3	3.3	9.2	4.5	9.5	7.0	7.3

<sup>1</sup> MSCI AC Asia Pacific ex-Japan Net Index (relevant currency)

Contact us	<b>Contact:</b> Susan Douse <b>Email:</b> <a href="mailto:susan.douse@douseassociates.com">susan.douse@douseassociates.com</a> <b>Telephone:</b> +44 1306 876 192 <b>Facsimile:</b> +44 1306 882 802 <b>Website:</b> <a href="http://www.maple-brownabbott.com.au">www.maple-brownabbott.com.au</a>
------------	---

This factsheet is issued by Maple-Brown Abbott Limited ("Maple-Brown Abbott") on behalf of Maple-Brown Abbott Funds plc (the "UCITS"), an open-ended umbrella investment company with variable capital and segregated liability between sub-funds, incorporated in Ireland and authorised by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities. The Maple-Brown Abbott Asia Pacific ex-Japan Fund (the "Sub-Fund") is a sub-fund of the UCITS and Maple-Brown Abbott (ABN 73 001 208 564, Australian Financial Services Licence No. 237296) is the UCITS' discretionary investment manager and distributor.

The information in this factsheet is intended solely for professional investors in the jurisdictions in which the Sub-Fund is registered for sale and should not be relied upon for any purpose. The information contained on this document is not directed at any person in any jurisdiction where the publication or availability of the information is prohibited or restricted by law. Information in this factsheet is for information purposes only and does not constitute an offer or solicitation by anyone in any jurisdiction. Nothing contained in the document constitutes financial, legal, tax or other advice of any kind. This factsheet is not, and must not be treated as, investment advice, investment recommendations, or investment research. Before making any investment decision, you should seek independent investment, legal, tax, accounting or other professional advice as appropriate.

The Sub-Fund's performance factsheet is based on the movement in net asset value per share plus dividends (where applicable) and is before tax and after all fees and charges. Tax credits are not included in the performance figures. Past performance is not a reliable indicator of future performance and prices for shares in the UCITS may fall as well as rise. An investment in the Sub-Fund does not represent an investment in, deposit with, or other liability of Maple-Brown Abbott, and is subject to investment risk, including possible delays in repayment and loss of income and principal invested. Neither Maple-Brown Abbott, the UCITS, nor any of their respective delegates, appointed service providers or other related parties, nor their respective directors or employees make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the income tax or other taxation consequences of, any investment. Any comments about individual stocks or other investments are not a recommendation to buy, sell or hold. Any views expressed on individual stocks or other investments are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this factsheet. Information contained in the factsheet that has not been derived directly from Maple-Brown Abbott has not been independently verified and may be subject to assumptions and qualifications of the relevant source and this factsheet does not purport to provide a complete description of all or any such assumptions and qualifications.

To the extent permitted by law, neither Maple-Brown Abbott, the UCITS, nor any of their respective delegates, appointed service providers or other related parties, nor their respective directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of the information contained in this factsheet, nor do they accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on any part of this factsheet.

Shares in the Sub-fund are issued by the UCITS. Before making a decision whether to acquire, or to continue to hold an investment in the Sub-Fund, investors should obtain and consider the current prospectus of the UCITS, as well as the supplement thereto in respect of the Sub-fund and the Key Investor Document(s) available at [www.maple-brownabbott.com.au/ucits](http://www.maple-brownabbott.com.au/ucits) or by calling +612 8226 6200. This information and the content of this factsheet is current as at 31 July 2020 and is subject to change at any time without notice.